Abstract 4904
Background
Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression in NS have the potential to provide novel targets for drug development. We hypothesized that there will be a difference in genomic profile of mUC in NS vs PCS.
Methods
Tumour tissue undergoing comprehensive genomic profiling (CGP) from patients with mUC were included from NS and age matched PCS within the same time period (2014-19). Clinical and CGP data were retrospectively collected. CGP was performed using FoundationOne (Foundation Medicine, Cambridge, MA), which provides exonic coverage of 315 genes.
Results
See table.Table:
943P
Non-smoker | Smoker | P value | |
---|---|---|---|
Median age at diagnosis, years (range) | 66.5 (33-86) | 67 (35-85) | 0.94 |
Site of primary | 0.009 | ||
Bladder | 37 (80%) | 39 (100%) | |
Upper tract | 9 (19.6%) | 0 | |
Urethral | 1 (<1%) | 0 | |
Gender | 0.001 | ||
Male | 32 | 38 | |
Female | 14 | 1 | |
Median number of genomic alterations (range) | 7 (1-17) | 7 (1-18) | 0.26 |
MLL2 gene alteration | 11 | 1 | 0.01 |
Conclusions
While the overall number of genomic alteration per patient and alteration frequencies were similar in NS vs PCS, we found a significantly higher frequency of MLL2 alterations in NS (p < 0.05). This finding is in agreement with previous reports of MLL2 alterations in UC; however, its significantly higher prevalence in NS is a novel finding and may suggest different oncogenic pathways in NS. It’s interesting to note that MLL2 alterations have been reported as drivers of self-renewal in bladder cancer stem cells (Yang et al, Euro Urol 2017, PMID 27387124).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Huntsman Cancer Institute.
Funding
Has not received any funding.
Disclosure
B.L. Maughan: Advisory / Consultancy: Peloton Therapeutics; Advisory / Consultancy: BMS; Advisory / Consultancy: Tempus; Advisory / Consultancy: Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Astellas Pharma. N. Agarwal: Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Exelixis; Honoraria (institution), Advisory / Consultancy: Eisai; Honoraria (institution), Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Foundation One; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Medivation; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Nektar; Honoraria (institution), Advisory / Consultancy: Genentech; Honoraria (institution), Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Pharmacyclics; Honoraria (institution): Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract